Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 164 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo inhalation solution Clear all

Conditions: Asthma
Interventions: Tiotropium low dose QD, Tiotropium high dose QD, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more

Conditions: Asthma
Interventions: Levalbuterol, Levalbuterol UDV TID, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Up to 48 Months
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 46
States / cities: Little Rock, Arkansas • Cypress, California • Long Beach, California + 35 more

Conditions: Anorexia Nervosa
Interventions: Isoproterenol, placebo; Drug · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
Interventions: Aerolized Hydroxychloroquine Sulfate, Placebo; Drug · Other
Lead sponsor: Pulmoquine Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 116
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: CMS, Placebo; Drug · Other
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Newport Beach, California • Palm Springs, California • Reseda, California + 22 more

Conditions: Pulmonary Arterial Hypertension
Interventions: L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution; Drug · Device · Other
Lead sponsor: Pharmosa Biopharm Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cystic Fibrosis
Interventions: Sodium Pyruvate in 0.9% Sodium Chloride Solution; Drug
Lead sponsor: Emphycorp; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions: arformoterol tartrate inhalation solution, Salmeterol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 65
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Allergic Asthma
Interventions: Placebo, Omalizumab, Immunotherapy; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, placebo, olodaterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more

Conditions: Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more

Conditions: Obstructive Sleep Apnea Syndrome
Interventions: Xyrem (X), Zolpidem (Z), Modafinil (M), Placebo (P); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 17,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 303
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more

Conditions: Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions: Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 12 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 54
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: COPD
Interventions: Arformoterol tartrate inhalation solution, Salmeterol MDI, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 52
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 49 more

Conditions: Upper Airway Obstruction
Interventions: Physostigmine, Oxygen, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cystic Fibrosis (CF)
Interventions: MP-376, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 16 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 39
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Anxiety and Fear
Interventions: Interoceptive Aversive Memory Reactivation, Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil, Placebo Oil; Behavioral · Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atelectasis, Ventilation, Mechanical
Interventions: Pulmozyme (nebulized dornase alpha), Saline; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: ARINA-1, Placebo; Drug
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Cystic Fibrosis
Interventions: Hypertonic Saline, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 5 Years to 12 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Augmented Interoceptive Exposure Training in Anorexia Nervosa

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

ACTIV-2: A Study for Outpatients With COVID-19

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phamacological Reversal of Airway Instability During Sedation

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Impact of CBD-Rich Oil on Aversive Memory Reconsolidation

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis